Evidence map›Paper›PMID 42207850›Full record

ArticlePloS one2026

Exfoliating effect of β-glycyrrhetinic acid on plaque inducing gingivitis: Comparison with cetylpyridinium chloride.

Shinya Kato, Xiangtao Ma, Kayo Sato, Aya Okumura, Nobuo Yoshinari, Akihiro Yoshida

Abstract readComparative Study
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shinya KatoDepartment of Periodontology, Faculty of Dentistry, Matsumoto Dental University, Shiojiri, Japan.
Xiangtao MaDepartment of Oral Health Promotion, Graduate School of Oral Medicine, Matsumoto Dental University, Shiojiri, Japan.
Kayo SatoHuman Health Care Product Research, Kao Corporation, Tokyo, Japan.
Aya OkumuraHuman Health Care Product Research, Kao Corporation, Tokyo, Japan.
Nobuo YoshinariDepartment of Periodontology, Faculty of Dentistry, Matsumoto Dental University, Shiojiri, Japan.
Akihiro YoshidaDepartment of Oral Microbiology, Faculty of Dentistry, Matsumoto Dental University, Shiojiri, Japan.ORCID https://orcid.org/0000-0003-1296-9022

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-glycyrrhetinic acid (BGA) possesses antibacterial effects against human supragingival plaque bacteria and inhibits biofilm formation. However, the effect of BGA on already formed dental plaque has not been investigated. We analyzed and compared the effects of BGA on preformed supragingival plaque biofilms with those of cetylpyridinium chloride (CPC). All experiments were performed in vitro using biofilms formed by incubating supragingival plaque bacteria for 24 h. First, we analyzed the number of viable and dead bacteria in the biofilms following BGA and CPC application. The number of viable bacteria was significantly reduced by BGA treatment compared with by the solvent control. However, the viable/dead bacterial ratios did not significantly vary. Conversely, the turbidity in the supernatants (optical density at 600 nm [OD600]) was 0.237 ± 0.003, 0.136 ± 0.002, and 0.096 ± 0.002 for the BGA, CPC, and solvent control groups, respectively, indicating superior ability of BGA in biofilm exfoliation. This study suggests that BGA may inhibit dental plaque adhesion and eliminate and disinfect dental plaque through a mechanism different from CPC, contributing to the prevention of periodontal disease.

Indexed as

Anti-Bacterial AgentsCetylpyridiniumDental PlaqueGingivitisGlycyrrhetinic AcidBiofilmsHumansAnti-Bacterial AgentsCetylpyridiniumGlycyrrhetinic Acid

Identifiers

PMID42207850
PMCPMC13218510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.